Focus on Patients

61. Pfizer To Provide Individual Participant Data At Scale 9/21/2023

    Historically, clinical trial participants have rarely gained possession of their individual trial data. But now, that's about to change. Pfizer is announcing plans to return individual data to its participants beginning this year.

62. Patients Are Speaking, And We Must Listen 9/7/2023

    Maimah Karmo knows all too well the importance of speaking up for oneself. Here, the president and CEO of Tigerlily Foundation shares what drove her to create the nonprofit and why she won't stop advocating for patients.

63. Recognizing Patients' Wants And Needs Benefits Sponsors, Regulators, And, Of Course, Patients 8/11/2023

    Most clinical trials fail to meet timelines, and the delay is typically caused by lagging patient enrollment. Patient advocates and consultants Richie Kahn and Jenn McNary say failed recruitment efforts often have to do with a fundamental mismatch between how a trial is designed and patients’ actual wants and needs.

64. Drug Development Must Meet Complex, Diverse Needs Of The Opioid Use Disorder Community 8/7/2023

    With almost 80,000 opioid overdose deaths in 2022, the surge in opioid-related overdoses and deaths in the United States has continued at a relentless pace. Treatments are available, but with more diverse therapies and flexible trial designs, more patients will be able to begin their journey to recovery. 

65. Shared Knowledge & Shared Data Is Crucial To Developing Innovative Therapies For SCIs 7/7/2023

    In this Q&A, Chief Science Officer Marco Baptista, Ph.D., discusses the Christopher & Dana Reeve Foundation's focus on and approach to data and knowledge sharing, as well as patient engagement, as it works to advocate for and fund the development of spinal cord injury (SCI) therapeutics.

66. Building Health Equity By Minimizing Barriers To Clinical Trial Participation 7/5/2023

    The pharmaceutical industry continuously works to address the unmet needs of patients, including the need for therapies that work for as many people as possible. Yet, we continue to see a lack of diversity in clinical trials. Janssen's Lisa Lewis details how we can all come together to improve patient diversity and improve outcomes for all people.

67. Advancing Alzheimer's Disease Treatment With An OLE, Expanded Access, & A Better Patient Experience 6/21/2023

    TrueBinding CEO Dongxu Sun, Ph.D. discusses the journey toward an Alzheimer’s disease drug that reduces (and reverses) symptoms — supported by an open label extension (OLE), compassionate use designation, and careful attention to patient experience.

68. Patient-Powered AI Is Driving Science And Innovation Forward 5/17/2023

    Drug discovery is a game of information: If we understand disease well, we know where to intervene and how to design a molecule to target the disease. AI can be used to integrate the patient experience and voice into solutions, further enhancing their relevance. 

69. Advancing Innovative Therapies For Mild-To-Moderate Psoriasis With Novel PASI-HD Assessment 5/8/2023

    The Psoriasis Area and Severity Index, or PASI, was developed in the 1970s as a tool for assessing the severity of psoriatic lesions for the purpose of assessing outcomes in a psoriasis clinical development program. But it falls short in assessing the severity of the disease in those wild mild to moderate psoriasis. Enter PASI-HD.

70. Patient-Centric Clinical Development For Rare Disease Treatments 4/28/2023

    Incorporating patients into every step of the process is integral to overcoming obstacles related to clinical development of rare disease treatments. Obtaining early patient input, designing meaningful clinical trials, and considering manufacturing strategy early is crucial.